Ileocolonic-Targeted JAK Inhibitor: A Safer and More Effective Treatment for Inflammatory Bowel Disease

Yadav, V; House, A; Matiz, S; McCoubrey, LE; Bettano, KA; Bhave, L; Wang, MY; Fan, P; Zhou, SQ; Woodhouse, JD; Poimenidou, E; Dou, L; Basit, AW; Moy, LY; Saklatvala, R; Hegde, LG; Yu, HS

Hegde, LG; Yu, HS (通讯作者)，Merck & Co Inc, 126 East Lincoln Ave,POB 2000, Rahway, NJ 07065 USA.

PHARMACEUTICS, 2022; 14 (11):

Abstract

Janus kinase (JAK) inhibitors, such as tofacitinib (Xeljanz) and filgotinib (Jyseleca), have been approved for treatment of ulcerative colitis with se......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索